Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study
Open accessAbstract
Background Animal and in vitro data suggest that dyslipidemia plays an important role in the initiation and progression of chronic renal disease, but few prospective studies have been conducted in humans. Methods We studied the relationship of plasma lipids to a rise in serum creatinine of 0.4 mg/dL or greater in 12,728 Atherosclerosis Risk in Communities (ARIC) participants with baseline serum creatinine that was less than 2.0 mg/dL in men and less than 1.8 mg/dL in women. Results During a mean follow-up of 2.9 years, 191 persons had a rise in creatinine of 0.4 mg/dL or greater, yielding an incidence rate of 5.1 per 1000 person years. Individuals with higher triglycerides and lower high-density lipoprotein (HDL) and HDL-2 cholesterol at baseline were at increased risk for a rise in creatinine after adjustment for race, gender, baseline age, diabetes, serum creatinine, systolic blood pressure, and antihypertensive medication use (all P trends </=0.02). The adjusted relative risk for the highest versus lowest quartile of triglycerides was 1.65 (95% CI, 1.1, 2.5, P = 0.01) and for HDL was 0.47 (95% CI, 0.3, 0.8, P = 0.003). These associations were significant in participants with normal creatinine (defined as <1.4 mg/dL for men and <1.2 mg/dL for women), with diabetes, and without diabetes. The effect of high triglycerides was independent of plasma glucose, but was weaker and less consistent after further adjustment for fasting insulin in nondiabetics. Conclusions High triglycerides and low HDL cholesterol, but not low-density lipoprotein cholesterol, predict an increased risk of renal dysfunction. The treatment of these lipid abnormalities may decrease the incidence of early renal disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HDL has been shown in animals and humans to be reno-protective.
“but has been shown in animals and humans to be reno-protective [35]”
From Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study (2011) · cites this paper as [35]
The Results passage (page unavailable in our copy) associates higher HDL cholesterol with a lower risk of a rise in creatinine in humans, but this observational finding does not show that HDL itself protects the kidney. The paper’s discussion of animal models reports reduced renal injury after lipid-lowering treatment, not a protective effect specifically attributable to HDL. (LLM, conf=0.87)
Experimental — accuracy not yet measuredDyslipidemia is a risk factor for progressive kidney disease.
“While dyslipidemia is a risk factor for progressive kidney disease (8,10,20,21)”
From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Blood Pressure, Systolic and Diastolic, and Cardiovascular Risks: US Population Data
Stamler, J. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410050036006 · Cited by 1,015 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults
Kurella, M., Lo, J. C., & Chertow, G. M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010106 · Cited by 709 · see citing works
Metabolic Syndrome and Kidney Disease: A Systematic Review and Meta-analysis
Thomas, G., Sehgal, A. R., Kashyap, S. R., Srinivas, T. R., Kirwan, J. P., & Navaneethan, S. D. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02180311 · Cited by 553 · see citing works
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401 · see citing works
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371 · see citing works
High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans
Bowe, B., Xie, Y., Xian, H., Balasubramanian, S., Zayed, M. A., & Al-Aly, Z. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00730116 · Cited by 213 · see citing works
Effects of Fibrates in Kidney Disease
Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189 · see citing works
Perfluoroalkyl Chemicals and Chronic Kidney Disease in US Adults
Shankar, A., Xiao, J., & Ducatman, A. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr171 · Cited by 166 · see citing works
Lipid and lipoprotein metabolism in chronic kidney disease.
Kaysen, G. A. (2009) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2008.10.011 · Cited by 102 · see citing works
CD36 and Na/K-ATPase-α1 Form a Proinflammatory Signaling Loop in Kidney
Kennedy, D. J., Chen, Y., Huang, W., Viterna, J., Liu, J., Westfall, K., Tian, J., Bartlett, D. J., Tang, W. H. W., Xie, Z., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.112.198770 · Cited by 101 · see citing works
Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes
Forsblom, C., Hiukka, A., Leinonen, E. S., Sundvall, J., Groop, P.-H., & Taskinen, M.-R. (2010) · Diabetes Care · doi:10.2337/dc09-0621 · Cited by 81 · see citing works
Wang, Y., He, W., Wei, W., Mei, X., Yang, M., & Wang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622737 · Cited by 30 · see citing works
- Authors
- Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J.
- Affiliations
- University of Minnesota (US)
- Johns Hopkins University (US)
- Corresponding author
- Coresh, Josef
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2000-07
- Volume
- 58
- Issue
- 1
- Pages
- 293-301
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2012766272
- Cited by
- 667
- References
- 2
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 18 · 2022: 28 · 2021: 40 · 2020: 26 · 2019: 25 · 2018: 26 · 2017: 16 · 2016: 39 · 2015: 26 · 2014: 28 · 2013: 32 · 2012: 32
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01hc55016-37-0-0, n01hc55019-35-0-1, n01hc55015-48-0-1)
- National Heart, Lung, and Blood Institute (N01 HC 55019, N01-HC55016, N01‐HC‐55015)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- plasma lipids, renal dysfunction, chronic kidney disease, triglycerides, HDL cholesterol, HDL2, LDL cholesterol, serum creatinine, dyslipidemia, diabetes mellitus, fasting insulin, Atherosclerosis Risk in Communities Study
- MeSH terms
- Arteriosclerosis, Creatinine, Female, Follow-Up Studies, Humans, Kidney Failure, Chronic, Cholesterol, HDL, Male, Middle Aged, Prospective Studies, Risk Factors, Triglycerides, Incidence, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review